About TRUVADA
TRUVADA is an anti-HIV-1 drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family. TRUVADA is a combination of 2 NRTIs (2-NRTI). TRUVADA is for use in combination with other HIV-1 medicines to treat HIV-1 infection in adults.
TRUVADA does not cure HIV-1 infection or AIDS and has not been shown to lower your chance of passing HIV-1 to others.
Once a day TRUVADA can help you reach undetectable (<400 copies/mL) — and keep you there.
TRUVADA is currently the #1 prescribed HIV medication.* Among African Americans, women and Latinos, more regimens are TRUVADA-based.*
The usual dose of TRUVADA is 1 tablet once a day in combination with other HIV meds. TRUVADA may be taken with or without a meal because food does not affect how TRUVADA works.
On November 3, 2008, the U.S. Department of Health and Human Services (DHHS) released an update of the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. For patients who are new to treatment ("treatment naïve"), the updated DHHS Guidelines list the meds in TRUVADA as the only preferred 2-NRTI option for use in combination HIV therapy.
TRUVADA is the #1 prescribed NRTI backbone with Reyataz® (atazanavir sulfate), Prezista® (darunavir), Lexiva® (fosamprenavir calcium), and Kaletra® (lopinavir/ritonavir).*
Next: Learn how the meds in TRUVADA work to help fight HIV
Patients should read the Patient Information, including "What is the most important information I should know about TRUVADA?". It is important that you discuss your treatment options and any questions that you may have with your healthcare provider.
*Synovate Healthcare Data; U.S. HIV Monitor, Q1, 2009.